{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:43:53Z","timestamp":1777301033594,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008769","name":"Universit\u00e4t W\u00fcrzburg","doi-asserted-by":"publisher","award":["398461692"],"award-info":[{"award-number":["398461692"]}],"id":[{"id":"10.13039\/501100008769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 105022\/58-1 FUGG"],"award-info":[{"award-number":["INST 105022\/58-1 FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004913","name":"Universit\u00e0 degli Studi di Palermo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004913","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.nano.2021.102451","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T11:51:02Z","timestamp":1627300262000},"page":"102451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Development of polymer-based nanoparticles for zileuton delivery to the lung: PMeOx and PMeOzi surface chemistry reduces interactions with mucins"],"prefix":"10.1016","volume":"37","author":[{"given":"Salvatore E.","family":"Drago","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela F.","family":"Craparo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Luxenhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennara","family":"Cavallaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2021.102451_bb0005","series-title":"Airway disease: similarities and differences between asthma, copd and bronchiectasis","author":"Athanazio","year":"2012"},{"key":"10.1016\/j.nano.2021.102451_bb0010","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.2147\/COPD.S270448","article-title":"Symptoms, management and healthcare utilization of COPD patients during the COVID-19 epidemic in Beijing","volume":"15","author":"Liang","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.nano.2021.102451_bb0015","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1517\/17425247.2011.588697","article-title":"Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management","author":"Marin","year":"2011","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.nano.2021.102451_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.addr.2018.04.010","article-title":"Delivering drugs to the lungs: the history of repurposing in the treatment of respiratory diseases","volume":"133","author":"Newman","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2021.102451_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2018.06.006","article-title":"Repurposing drugs as inhaled therapies in asthma","author":"Anderson","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"17","key":"10.1016\/j.nano.2021.102451_bb0030","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJM199210223271704","article-title":"Tolerance to the nonbronchodilator effects of inhaled \u03b22-agonists in asthma","volume":"327","author":"O\u2019Connor","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2021.102451_bb0035","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","article-title":"Glucocorticoid resistance in inflammatory diseases","author":"Barnes","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.nano.2021.102451_bb0040","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","author":"Lai","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2021.102451_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2019.10.035","article-title":"Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy","author":"He","year":"2019","journal-title":"J Control Release"},{"issue":"13","key":"10.1016\/j.nano.2021.102451_bb0050","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.biomaterials.2013.01.064","article-title":"Nanoparticle diffusion in respiratory mucus from humans without lung disease","volume":"34","author":"Schuster","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2021.102451_bb0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","article-title":"Barrier properties of mucus","author":"Cone","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2021.102451_bb0060","first-page":"571","article-title":"Perspective series innate defenses in the lung","volume":"109","author":"Whitsett","year":"2002","journal-title":"J Clin Invest"},{"issue":"6097","key":"10.1016\/j.nano.2021.102451_bb0065","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1126\/science.1223012","article-title":"A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia","volume":"337","author":"Button","year":"2012","journal-title":"Science (80- )"},{"key":"10.1016\/j.nano.2021.102451_bb0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.addr.2017.11.002","article-title":"The role of mucus as an invisible cloak to transepithelial drug delivery by nanoparticles","author":"Garc\u00eda-D\u00edaz","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.nano.2021.102451_bb0075","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.nano.2016.11.017","article-title":"Nanoparticle passage through porcine jejunal mucus: microfluidics and rheology","volume":"13","author":"Bhattacharjee","year":"2017","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1016\/j.nano.2021.102451_bb0080","series-title":"Interactions of microbicide nanoparticles with a simulated vaginal fluid","author":"Neves","year":"2012"},{"issue":"3","key":"10.1016\/j.nano.2021.102451_bb0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/nnm.13.26","article-title":"Development and in vitro evaluation of slippery nanoparticles for enhanced diffusion through native mucus","volume":"9","author":"Laffleur","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2021.102451_bb0090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","author":"Ensign","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2021.102451_bb0095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejpb.2015.01.014","article-title":"Steric and interactive barrier properties of intestinal mucus elucidated by particle diffusion and peptide permeation","volume":"95","author":"Boegh","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"issue":"11","key":"10.1016\/j.nano.2021.102451_bb0100","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/(SICI)1097-4628(19970314)63:11<1481::AID-APP10>3.0.CO;2-5","article-title":"Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin","volume":"63","author":"Norris","year":"1997","journal-title":"J Appl Polym Sci"},{"key":"10.1016\/j.nano.2021.102451_bb0105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.addr.2017.10.001","article-title":"Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties","author":"Wu","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.nano.2021.102451_bb0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/pharmaceutics12020089","article-title":"Design of new polyaspartamide copolymers for SiRNA delivery in antiasthmatic therapy","volume":"12","author":"Craparo","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.nano.2021.102451_bb0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/acsami.7b14992","article-title":"Mucus and cell-penetrating nanoparticles embedded in nano-into-micro formulations for pulmonary delivery of ivacaftor in patients with cystic fibrosis","volume":"10","author":"Porsio","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"issue":"43","key":"10.1016\/j.nano.2021.102451_bb0120","doi-asserted-by":"crossref","first-page":"7978","DOI":"10.1002\/anie.200901607","article-title":"Poly(2-oxazoline)s: a polymer class with numerous potential applications","volume":"48","author":"Hoogenboom","year":"2009","journal-title":"Angew Chem Int Ed"},{"issue":"19","key":"10.1016\/j.nano.2021.102451_bb0125","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/marc.201200453","article-title":"Poly(2-oxazoline)s \u2014 are they more advantageous for biomedical applications than other polymers?","volume":"33","author":"Sedlacek","year":"2012","journal-title":"Macromol Rapid Commun"},{"key":"10.1016\/j.nano.2021.102451_bb0130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.biomaterials.2018.05.022","article-title":"Poly(2-oxazoline)s based biomaterials: a comprehensive and critical update","volume":"178","author":"Lorson","year":"2018","journal-title":"Biomaterials"},{"issue":"30","key":"10.1016\/j.nano.2021.102451_bb0135","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1039\/C5TB00901D","article-title":"Properties and reactivity of polyoxazoline plasma polymer films","volume":"3","author":"Macgregor-Ramiasa","year":"2015","journal-title":"J Mater Chem B"},{"issue":"6","key":"10.1016\/j.nano.2021.102451_bb0140","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/mds.28027","article-title":"Once-weekly subcutaneous delivery of polymer-linked rotigotine (SER-214) provides continuous plasma levels in Parkinson\u2019s disease patients","volume":"35","author":"Olanow","year":"2020","journal-title":"Mov Disord"},{"issue":"32","key":"10.1016\/j.nano.2021.102451_bb0145","doi-asserted-by":"crossref","first-page":"13671","DOI":"10.1039\/C5NR03178H","article-title":"POZylation: a new approach to enhance nanoparticle diffusion through mucosal barriers","volume":"7","author":"Mansfield","year":"2015","journal-title":"Nanoscale"},{"issue":"9","key":"10.1016\/j.nano.2021.102451_bb0150","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1039\/C6BM00375C","article-title":"Side chain variations radically alter the diffusion of poly(2-alkyl-2-oxazoline) functionalised nanoparticles through a mucosal barrier","volume":"4","author":"Mansfield","year":"2016","journal-title":"Biomater Sci"},{"issue":"5","key":"10.1016\/j.nano.2021.102451_bb0155","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1021\/bc200049d","article-title":"Polyoxazoline: chemistry, properties, and applications in drug delivery","volume":"22","author":"Viegas","year":"2011","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.nano.2021.102451_bb0160","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jconrel.2007.02.015","article-title":"Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s","volume":"119","author":"Gaertner","year":"2007","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2021.102451_bb0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.addr.2014.05.017","article-title":"Delivery strategies for sustained drug release in the lungs","author":"Loira-Pastoriza","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2021.102451_bb0170","doi-asserted-by":"crossref","first-page":"119304","DOI":"10.1016\/j.ijpharm.2020.119304","article-title":"Inhalable nano into micro dry powders for ivacaftor delivery: the role of mannitol and cysteamine as mucus-active agents","volume":"582","author":"Porsio","year":"2020","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.nano.2021.102451_bb0175","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.2042-7158.2012.01486.x","article-title":"Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises","volume":"64","author":"Ungaro","year":"2012","journal-title":"J Pharm Pharmacol"},{"issue":"24","key":"10.1016\/j.nano.2021.102451_bb0180","doi-asserted-by":"crossref","first-page":"8649","DOI":"10.1016\/S0032-3861(00)00185-3","article-title":"Molecular characterization of \u03b1,\u03b2-poly[(N-hydroxyethyl)-DL-aspartamide] by light scattering and viscometry studies","volume":"41","author":"Mendichi","year":"2000","journal-title":"Polymer (Guildf)"},{"issue":"May","key":"10.1016\/j.nano.2021.102451_bb0185","doi-asserted-by":"crossref","first-page":"122596","DOI":"10.1016\/j.polymer.2020.122596","article-title":"Production of polymeric micro- and nanostructures with tunable properties as pharmaceutical delivery systems","volume":"200","author":"Craparo","year":"2020","journal-title":"Polymer (Guildf)"},{"key":"10.1016\/j.nano.2021.102451_bb0190","doi-asserted-by":"crossref","first-page":"119641","DOI":"10.1016\/j.ijpharm.2020.119641","article-title":"Effect of actively targeted copolymer coating on solid tumors eradication by gold nanorods-induced hyperthermia","volume":"587","author":"Puleio","year":"2020","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.nano.2021.102451_bb0195","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijpharm.2015.09.050","article-title":"PHEA-PLA biocompatible nanoparticles by technique of solvent evaporation from multiple emulsions","volume":"495","author":"Cavallaro","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2021.102451_bb0200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejmech.2017.10.020","article-title":"Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma","volume":"153","author":"Bruno","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.nano.2021.102451_bb0205","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1742-1241.2007.01320.x","article-title":"Clinical implications of 5-lipoxygenase inhibition in severe airway disease","author":"Berger","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.nano.2021.102451_bb0210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejmech.2017.07.019","article-title":"Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis","author":"G\u00fcr","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.nano.2021.102451_bb0215","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jlac.197419740615","article-title":"Cyclische Imids\u00e4ureester Aus Nitrilen Und Aminoalkoholen","volume":"1974","author":"Witte","year":"1974","journal-title":"Justus Liebigs Ann Chem"},{"key":"10.1016\/j.nano.2021.102451_bb0220","series-title":"Drug specificity, synergy and antagonism in ultrahigh capacity poly(2-oxazoline)\/poly(2-oxazine) based formulations","author":"L\u00fc","year":"2017"},{"issue":"8","key":"10.1016\/j.nano.2021.102451_bb0225","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s003960100492","article-title":"New biodegradable hydrogels based on a photo-cross-linkable polyaspartamide and poly(ethylene glycol) derivatives. release studies of an anticancer drug","volume":"279","author":"Giammona","year":"2001","journal-title":"Colloid Polym Sci"},{"key":"10.1016\/j.nano.2021.102451_bb0230","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.polymer.2015.06.009","article-title":"Hepatocyte-targeted fluorescent nanoparticles based on a polyaspartamide for potential theranostic applications","volume":"70","author":"Craparo","year":"2015","journal-title":"Polymer (Guildf)"},{"issue":"2","key":"10.1016\/j.nano.2021.102451_bb0235","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/jbm.a.31316","article-title":"Crosslinked hyaluronan with a protein-like polymer: novel bioresorbable films for biomedical applications","volume":"84","author":"Pitarresi","year":"2008","journal-title":"J Biomed Mater Res Part A"},{"key":"10.1016\/j.nano.2021.102451_bb0240","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2014.05.008","article-title":"Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies","author":"d\u2019Angelo","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.nano.2021.102451_bb0245","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1124\/jpet.106.115436","article-title":"Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton","volume":"321","author":"Rao","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nano.2021.102451_bb0250","series-title":"Leukotriene B 4 mediates histamine induction of NF-B and IL-8 in human bronchial epithelial cells","volume":"Vol. 274","author":"Aoki","year":"1998"},{"issue":"6","key":"10.1016\/j.nano.2021.102451_bb0255","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/bit.23046","article-title":"Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model","volume":"108","author":"Yang","year":"2011","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"10.1016\/j.nano.2021.102451_bb0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/nnm-2016-0262","article-title":"Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis","volume":"12","author":"Craparo","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2021.102451_bb0265","series-title":"Nano into micro formulations of tobramycin for the treatment of pseudomonas aeruginosa infections in cystic fibrosis","author":"Porsio","year":"2017"},{"key":"10.1016\/j.nano.2021.102451_bb0270","series-title":"Pegylated polyaspartamide\u2212polylactide-based nanoparticles penetrating cystic fibrosis artificial mucus","author":"Craparo","year":"2016"},{"key":"10.1016\/j.nano.2021.102451_bb0275","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.coph.2004.01.011","article-title":"Airway mucus hypersecretion in asthma: an undervalued pathology?","author":"Rogers","year":"2004","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"10.1016\/j.nano.2021.102451_bb0280","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/jcm6120112","article-title":"Airway mucus and asthma: the role of MUC5AC and MUC5B","volume":"6","author":"Bonser","year":"2017","journal-title":"J Clin Med"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963421000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963421000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:15:59Z","timestamp":1761549359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963421000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":56,"alternative-id":["S1549963421000940"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2021.102451","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of polymer-based nanoparticles for zileuton delivery to the lung: PMeOx and PMeOzi surface chemistry reduces interactions with mucins","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2021.102451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102451"}}